Recombinant human hyaluronidase Hyal-1:: insect cells versus Escherichia coli as expression system and identification of low molecular weight inhibitors

被引:38
作者
Hofinger, Edith S. A.
Spickenreither, Martin
Oschmann, Jan
Bernhardt, Guenther
Rudolph, Rainer
Buschauer, Armin [1 ]
机构
[1] Univ Regensburg, Inst Pharm, Lehrstuhl Pharmazeut & Med Chem 2, D-93053 Regensburg, Germany
[2] Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle, Saale, Germany
[3] Novoplant GmbH, D-06466 Gatersleben, Germany
关键词
Drosophila Schneider-2 cells; Hyal-1; hyaluronidase; inhibitors; protein folding;
D O I
10.1093/glycob/cwm003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The human hyaluronidase Hyal-1, one of six human hyaluronidase subtypes, preferentially degrades hyaluronic acid present in the extracellular matrix of somatic tissues. Modulations of Hyal-1 expression have been observed in a number of malignant tumors. However, its role in disease progression is discussed controversially due to limited information on enzyme properties as well as the lack of specific inhibitors. Therefore, we expressed human Hyal-1 in a prokaryotic and in an insect cell system to produce larger amounts of the purified enzyme. In Escherichia coli, Hyal-1 formed inclusion bodies and was refolded in vitro after purification by metal ion affinity chromatography. However, the enzyme was produced with extremely low folding yields (0.5%) and exhibited a low specific activity (0.1 U/mg). Alternatively, Hyal-1 was secreted into the medium of stably transfected Drosophila Schneider-2 (DS-2) cells. After several purification steps, highly pure enzyme with a specific activity of 8.6 U/mg (consistent with the reported activity of human Hyal-1 from plasma) was obtained. Both Hyal-1 enzymes showed pH profiles similar to the hyaluronidase of human plasma with an activity maximum at pH 3.5-4.0. Deglycosylation of Hyal-1, expressed in DS-2 cells, resulted in a decrease in the enzymatic activity determined by a colorimetric hyaluronidase activity assay. Purified Hyal-1 from DS-2 cells was used for the investigation of the inhibitory activity of new ascorbic acid derivatives. Within this series, l-ascorbic acid tridecanoate was identified as the most potent inhibitor with an IC50 of 50 +/- 4 mu M comparable with glycyrrhizic acid.
引用
收藏
页码:444 / 453
页数:10
相关论文
共 55 条
[31]  
Mayer Marcus, 2004, Methods Mol Med, V94, P239
[32]   Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses [J].
Menzel, EJ ;
Farr, C .
CANCER LETTERS, 1998, 131 (01) :3-11
[33]   Inhibitors of the hyaluronidases [J].
Mio, K ;
Stern, R .
MATRIX BIOLOGY, 2002, 21 (01) :31-37
[34]  
Misawa S, 1999, BIOPOLYMERS, V51, P297, DOI 10.1002/(SICI)1097-0282(1999)51:4<297::AID-BIP5>3.0.CO
[35]  
2-I
[36]   Quantitation of hyaluronidases by the Morgan-Elson reaction: comparison of the enzyme activities in the plasma of tumor patients and healthy volunteers [J].
Muckenschnabel, I ;
Bernhardt, C ;
Spruss, T ;
Dietl, B ;
Buschauer, A .
CANCER LETTERS, 1998, 131 (01) :13-20
[37]   Aberrant serum hyaluronan and hyaluronidase levels in scleroderma [J].
Neudecker, BA ;
Stern, R ;
Connolly, MK .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (03) :469-476
[38]  
Ni X, 2006, HISTOL HISTOPATHOL, V21, P899, DOI 10.14670/HH-21.899
[39]   Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer [J].
Paiva, P ;
Van Damme, MP ;
Tellbach, M ;
Jones, RL ;
Jobling, T ;
Salamonsen, LA .
GYNECOLOGIC ONCOLOGY, 2005, 98 (02) :193-202
[40]  
Posey JT, 2003, CANCER RES, V63, P2638